Earnings summaries and quarterly performance for PALISADE BIO.
Executive leadership at PALISADE BIO.
Board of directors at PALISADE BIO.
Research analysts covering PALISADE BIO.
Recent press releases and 8-K filings for PALI.
Palisade Bio to Present at Oppenheimer Healthcare Conference
PALI
New Projects/Investments
- Palisade Bio's CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, from 12:40 PM to 1:10 PM ET.
- The presentation will highlight PALI-2108, a once-daily oral PDE4 inhibitor prodrug, which demonstrated a 100% clinical response in the UC cohort during a Phase 1b trial with favorable tolerability and no serious adverse events.
- The company is advancing PALI-2108 towards a Phase 2 clinical study in Ulcerative Colitis (UC) and is conducting early studies in FSCD.
2 days ago
Palisade Bio Announces PALI-2108 Abstracts Selected for IBD Conferences
PALI
New Projects/Investments
- Palisade Bio announced that two abstracts highlighting its lead program, PALI-2108, were selected for poster presentations at two premier international inflammatory bowel disease (IBD) meetings in early 2026.
- PALI-2108 is a clinical-stage, once-daily, oral PDE4 inhibitor prodrug designed for targeted delivery to the terminal ileum and colon.
- In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events.
- The company is advancing PALI-2108 towards a Phase 2 clinical study in UC and preparing to initiate studies in fibrostenotic Crohn’s Disease (FSCD).
Jan 16, 2026, 1:30 PM
Palisade Bio Secures Japanese Patent for PALI-2108
PALI
New Projects/Investments
- The Japan Patent Office (JPO) has granted Palisade Bio, Inc. a key patent covering PALI-2108, the company's lead gut-microbiota-activated PDE4 B/D inhibitor.
- This patent provides composition-of-matter protection for PALI-2108 in Japan, with a base term extending into 2041.
- The issuance strengthens Palisade Bio's global intellectual property estate, particularly in Japan, which is a significant market for inflammatory bowel disease (IBD).
- PALI-2108 has completed Phase 1a/1b studies, and data from these are expected to support Phase 2 Investigational New Drug (IND) submissions to the U.S. FDA in the first half of 2026 for ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).
Dec 30, 2025, 1:35 PM
Palisade Bio Outlines 2026-2027 Milestones and Recent Fundraising
PALI
New Projects/Investments
Guidance Update
- Palisade Bio anticipates key milestones in 2026 and 2027, including a Phase 1B readout for fibrostenotic Crohn's disease in early Q1 2026, filing an IND for a definitive ulcerative colitis (UC) study in mid-2026, and a final top-line readout for the UC study around end of 2027.
- The company's lead drug, PALI-2108, is a next-generation PDE4 inhibitor formulated as an oral, once-daily prodrug that is activated locally in the gut, aiming to avoid systemic adverse events common with other PDE4 inhibitors. It is also 20 times more potent than Apremilast and acts as both an anti-inflammatory and antifibrotic agent.
- Earlier data from a small 5-patient cohort showed 100% clinical response and 40% clinical remission in UC patients after one week of PALI-2108 treatment, alongside a 70% reduction in fecal calprotectin. A definitive Phase 2 UC study, designed to be potentially registrational, will enroll 65 patients per arm (high, low, placebo) with IND clearance and study start expected in 1H 2026.
- Palisade Bio recently completed a fundraising round, securing $138 million from blue-chip investors, providing sufficient cash to complete Phase 2 studies in both UC and fibrostenotic Crohn's disease and ensuring at least a year and a half of runway post-study completion.
Dec 4, 2025, 3:30 PM
Palisade Bio Outlines 2026-2027 Milestones and Financial Position
PALI
Guidance Update
New Projects/Investments
- Palisade Bio (PALI) anticipates key clinical milestones in 2026 and 2027, including a Phase 1B readout for fibrostenotic Crohn's disease in early Q1 2026, an IND filing for a definitive Ulcerative Colitis (UC) study mid-2026, and a final top-line readout for the UC study by the end of 2027.
- The company's lead drug, PALI-2108, is a next-generation PDE4 inhibitor utilizing a prodrug formulation for local delivery in the gut, designed to avoid systemic toxicities while being 20 times more potent than Apremilast.
- Early data for PALI-2108 in UC patients showed a 100% clinical response and 40% clinical remission in a five-patient cohort after one week, alongside significant biomarker improvements such as a 70% reduction in fecal calprotectin.
- Palisade Bio recently completed a $138 million fundraising round, securing sufficient cash to complete Phase 2 studies in both UC and fibrostenotic Crohn's disease, with at least 1.5 years of runway post-study completion.
Dec 4, 2025, 3:30 PM
Palisade Bio closes $138 million public offering
PALI
New Projects/Investments
- Palisade Bio, Inc. announced the closing of its underwritten public offering on October 02, 2025, raising approximately $138 million in gross proceeds, including the full exercise of the over-allotment option.
- The offering comprised 197,154,844 shares of common stock (or common stock equivalents) at a public offering price of $0.70 per share.
- The proceeds are intended to support the upcoming Phase 2 clinical development program for PALI-2108 in Ulcerative Colitis.
- The offering was led by B Group Capital and Columbia Threadneedle Investments, with significant participation from other investors.
Oct 2, 2025, 8:05 PM
Palisade Bio Prices $120 Million Public Offering
PALI
- Palisade Bio, Inc. (PALI) announced the pricing of an underwritten public offering of 171,440,559 shares of its common stock (or common stock equivalents) at a public offering price of $0.70 per share.
- The offering is expected to generate approximately $120 million in gross proceeds, before deductions.
- The underwriters have been granted a 45-day option to purchase up to an additional 25,714,285 shares of common stock.
- The offering is anticipated to close on or about October 2, 2025.
Oct 1, 2025, 1:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more